IOB - Delayed Quote USD

Pfizer Inc. (0Q1N.IL)

23.00
+0.38
+(1.66%)
As of 9:00:04 AM GMT+1. Market Open.
Loading Chart for 0Q1N.IL
  • Previous Close 22.62
  • Open 22.68
  • Bid 21.45 x --
  • Ask 24.05 x --
  • Day's Range 22.68 - 23.00
  • 52 Week Range 20.77 - 27.54
  • Volume 3,230
  • Avg. Volume 282,982
  • Market Cap (intraday) 139.397B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 6.12
  • EPS (TTM) 3.76
  • Earnings Date Jul 28, 2025 - Aug 1, 2025
  • Forward Dividend & Yield 1.64 (5.31%)
  • Ex-Dividend Date Nov 8, 2023
  • 1y Target Est --

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

83,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0Q1N.IL

View More

Performance Overview: 0Q1N.IL

Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

0Q1N.IL
9.99%
S&P 500 (^GSPC)
1.30%

1-Year Return

0Q1N.IL
3.09%
S&P 500 (^GSPC)
12.35%

3-Year Return

0Q1N.IL
45.78%
S&P 500 (^GSPC)
52.75%

5-Year Return

0Q1N.IL
18.07%
S&P 500 (^GSPC)
103.85%

Compare To: 0Q1N.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0Q1N.IL

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    129.80B

  • Enterprise Value

    173.77B

  • Trailing P/E

    16.39

  • Forward P/E

    7.75

  • PEG Ratio (5yr expected)

    0.57

  • Price/Sales (ttm)

    2.07

  • Price/Book (mrq)

    1.42

  • Enterprise Value/Revenue

    2.78

  • Enterprise Value/EBITDA

    10.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.55%

  • Return on Assets (ttm)

    7.63%

  • Return on Equity (ttm)

    23.07%

  • Revenue (ttm)

    77.94B

  • Net Income Avi to Common (ttm)

    21.49B

  • Diluted EPS (ttm)

    3.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.79B

  • Total Debt/Equity (mrq)

    66.14%

  • Levered Free Cash Flow (ttm)

    12.35B

Research Analysis: 0Q1N.IL

View More

Company Insights: 0Q1N.IL

Research Reports: 0Q1N.IL

View More

People Also Watch